

INFORMATII PERSONALE SABINA IOANA DOINITA ILUTA



LOCUL DE MUNCA

Spitalul Clinic Judetean de Urgenta Bistrita, Sectia Oncologie Medicala

POZIȚIA

Medic Specialist Hematolog

EXPERIENTA
PROFESIONALA

Perioada	Ocupatia	Angajator
Martie 2022- prezent	Medic specialist hematolog	Departamentul de Hematologie, Spitalul Judetean de urgente Oradea, Romania - contract de garzi
Februarie 2021- Februarie 2022	Medic rezident hematolog	Departamentul de Hematologie, Spitalul Judetean de urgente Oradea, Romania - contract de garzi
Martie 2022- prezent	Medic specialist hematolog	Departamentul de Hematologie din cadrul Institutului Oncologic ” Prof Dr. Ion Chiricuta” Cluj-Napoca, Romania- contract de garzi
Decembrie 2022- prezent	Medic specialist hematolog	Clinica Lavinia Davidescu, Oradea

Octombrie 2021-prezent	Membru Societatea Japoneza de Hematologie	
Iunie 2022-prezent	Membru Societatea Europeana de Hematologie	

EDUCATIE SI FORMARE

1999-2010	Liceul „Nicolae Jiga” Tinca, Bihor, clasele I-IV, V-VIII, IX-XII	
2010 - 2016	Student	Facultatea de Medicina si Farmacie a Universitatii Oradea
2015-2016	Voluntar	Departamentul de Urgenta Spitalul Judetean Oradea
2016 - 2021	Rezident Hematologie	Departamentul de Hematologie din cadrul Institutului Oncologic ” Prof Dr. Ion Chiricuta” Cluj-Napoca
Octombrie 2019-prezent	Student Doctorand	Universitatea de Medicina si Farmacie Iuliu Hatieganu Cluj-Napoca

COMPETENTE PERSONALE

Limba maternă : română
Limbi străine : engleză B2

COMPETENȚE /ATESTATE

Competenta in ultrasonografie generala - 2025

INFORMATII
SUPLIMENTARE

EXPERIENTA IN TRIALURI CLINICE

No.	Acronym	Title	Sponsor / International investigator	Role in the study
1.	A phase III, double-blind, placebo controlled study of Quizartinib (AC220)	AC220-A-U302- A phase III, double-blind, placebo controlled study of Quizartinib (AC220) administered in combination with induction and consolidation chemotherapy, and administered as maintenance therapy in subjects 18 to 75 years old with newly diagnosed FLT3-ITD(+) acute myeloid leukemia Quizartinib advancement into the next generation	DAICHI	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca March 2019-present
2.	CURRENT	Real World Treatment Patterns and Clinical Outcomes in Unfit AML Patients Receiving First Line Systemic Treatment or Best Supportive Care. H19-473	ABBVIE	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca August 2019-March 2020
3.	SAMSUNG BIOEPIS	A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB12 (proposed eculizumab biosimilar) and Solirisin Subjects with Paroxysmal Nocturnal Haemoglobinuria	SAMSUNG	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca October 2019-March 2023
4.	FORWARD STUDY	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	RIGEL	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca September 2020-September 2022

5.	PAREXEL TELIOS	A randomized open-label ravulizumab controlled study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria who are complement inhibitor treatment-naïve or have not recently received complement inhibitor therapy	REGENERON PHARMECEUTI CALIS	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca November 2020- present
6.	KEROS	A Phase 2, Inpatient Dose Titration Study of KER-047 in Participants with Functional Iron Deficiency Anemia Associated with Myelodysplastic Syndromes, Myelofibrosis, and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes	KEROS THERAPEUTICS	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca March 2022- present
7.	CA057-001	A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)	BRISTOL MYERS SQUIBB	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca February 2023- present
8.	PACIFICA	A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts	CTI BioPharma Corp	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca June 2023-present
8.	M22-003	A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)	ABBVIE	Study Coordinator for Ion Chiricuta Oncology Institute Cluj Napoca June 2024-present

9.	INDEPENDENCE	A phase 3, double blind, randomized study to compare the efficacy and safety of luspaterecept versus placebo in subjects with myeloproliferative neoplasm-associated myelofibrosis on concomitant JAK2 inhibitor therapy and who require red blood cell transfusions	CELGENE	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca May 2023-present
10.	CA011-023	A phase 1b , open-label, dose-finding study to assess the safety, tolerability and preliminary efficacy of BMS-986158 monotherapy and in combination with either Fedratinib or Ruxolitinib in subjects with DIPSS-Intermediate or high risk myelofibrosis	BRISTOL MYERS SQUIBB	Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca May 2023-present
11.	T CELL Project - retrospective and prospective study on patients diagnosed with T Cell Lymphomas in collaboration with the European Institute of Oncology Milan, Italy			Sub-Investigator for Ion Chiricuta Oncology Institute Cluj Napoca July 2021- present
12.	LUIPIAE Registry for relapsed/refractory Follicular Lymphoma in collaboration with the European Institute of Oncology Milan, Italy			Site Data Manager for Ion Chiricuta Oncology Institute Cluj Napoca March 2022- present

ARTICOLE PUBLICATE

1. [Wnt Signaling Pathway in Tumor Biology](#). **Iluta S**, Nistor M, Buruiana S, Dima D. *Genes* (Basel). 2024 Dec 13;15(12):1597. doi: 10.3390/genes15121597. PMID: 39766864

2. [Notch and Hedgehog Signaling Unveiled: Crosstalk, Roles, and Breakthroughs in Cancer Stem Cell Research](#). **Iluta S**, Nistor M, Buruiana S, Dima D. *Life* (Basel). 2025 Feb 4;15(2):228. doi: 10.3390/life15020228. PMID: 40003637

3. [Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.](#) **Iluta S**, Pasca S, Gafencu G, Jurj A, Terec A, Teodorescu P, Selicean C, Jitaru C, Preda A, Cenariu D, Constantinescu C, Iordache M, Tigu B, Munteanu R, Feder R, Dima D, Zdrenghia M, Gulei D, Ciuleanu TE, Tomuleasa C. *J Cell Mol Med.* 2021 Jul;25(13):6094-6102. doi: 10.1111/jcmm.16513. Epub 2021 Jun 16. PMID: 34132464
4. Real-World Treatment Patterns and Clinical Outcomes in Unfit AML Patients: Results of Current Retrospective Study in Romania **Sabina ILUTA**^{1,2}, Angela Smaranda DASCALESCU^{3,4*}, Alexandra Elena GHIAUR⁵, Ciprian TOMULEASA^{1,2}, Geanina STINGU
5. [RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes.](#) Gulei D, Moisoiu V, Kegyes D, Drula R, **Iluta S**, Tigu AB, Nistor M, Jitaru C, Bancos A, Rotariu P, Popovici C, Dima D, Tomai R, Rus I, Constantinescu C, Munteanu R, Cenariu D, Sezerman U, Zdrenghia M, Cermak J, Einsele H, Ghiaur G, Tomuleasa C. *J Cell Mol Med.* 2024 Sep;28(18):e70078. doi: 10.1111/jcmm.70078. PMID: 39334509
6. [Extramedullary Hematopoiesis of the Liver and Spleen.](#) Cenariu D, **Iluta S**, Zimta AA, Petrushev B, Qian L, Dirzu N, Tomuleasa C, Bumbea H, Zaharie F. *J Clin Med.* 2021 Dec 13;10(24):5831. doi: 10.3390/jcm10245831. PMID: 34945127
7. [Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.](#) Drula R, **Iluta S**, Gulei D, Iuga C, Dima D, Ghiaur G, Buzoianu AD, Ciechanover A, Tomuleasa C. *Blood Rev.* 2022 Nov;56:100971. doi: 10.1016/j.blre.2022.100971. Epub 2022 May 16. PMID: 35595613
8. [Characterization of extrachromosomal circular DNA in patients with acute myeloid leukemia: proof-of-concept report using cohorts from Beijing and Shanghai.](#) Qian L, Xia X, Liu J, Chen X, Liu Y, Wang X, **Iluta S**, Pasca S, Gulei D, Tomuleasa C. *Ann Transl Med.* 2022 Aug;10(15):843. doi: 10.21037/atm-22-1498. PMID: 36035011 **Free PMC article**
9. [Approach to the Adult Acute Lymphoblastic Leukemia Patient.](#) Sas V, Moisoiu V, Teodorescu P, Tranca S, Pop L, **Iluta S**, Pasca S, Blag C, Man S, Roman A, Constantinescu C, Rus I, Buse M, Fetica B, Marian M, Selicean C, Berindan-Neagoe I, Petrushev B, Bumbea H, Tanase A, Zdrenghia M, Fuji S, Kitano S, Tomuleasa C; Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation.
10. [Transient leukemia of Down syndrome.](#) Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, **Iluta S**, Zdrenghia M, Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C.
11. [SERS-based assessment of MRD in acute promyelocytic leukemia](#) Cristina Turcas, Vlad Moisoiu, Andrei Stefanu, Ancuta Jurj, Stefania D Iancu, Patric Teodorescu, Sergiu Pasca, Anca Bojan, Adrian Trifa, **Sabina Ioana Iluta**, Alina-Andreea Zimta, Bobe Petrushev, Mihnea Zdrenghia, Horia Bumbea, Daniel Coriu, Delia Dima, Nicolae Leopold, Ciprian Tomuleasa
12. [Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab](#) Ciprian Tomuleasa, **Sabina Iluta**, Sergiu Pasca, Andrei Roman, Doina Piciu, Ciprian Jitaru, Patric Teodorescu, Ioana Rus, Anca Bojan, Delia Dima, Mihnea Zdrenghia, Bobe Petrushev.
13. [Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia](#) Dalma Deak, Cristina Pop, Alina-Andreea Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Patric Teodorescu, Angela Dascalescu, Ion Antoh, Bogdan Ionescu, Catalin Constantinescu, Anca Onaciu, Raluca Munteanu, Ioana Berindan-Neagoe, Bobe Petrushev, Cristina Turcas, **Sabina Iluta**, Cristina Selicean, Mihnea Zdrenghia, Alina

Tanase, CatalinDanaila, Anca Colita, Andrei Colita, Delia Dima, Daniel Coriu², Hermann Einseleand CiprianTomuleasa.

14. [Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies](#)

Catalin Constantinescu; Sergiu Pasca; Alina-AndreeaZimta; Tiberiu Tat; Ioana Rus; Patric Teodorescu; **Sabina Iluta**; Alina Tanase; Anca Colita; Olafur Sigurjonsson; Hermann Einsele; CiprianTomuleasa

15. [Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP](#)

Sabina Iluta , Dragos-AlexandruTermure, BobePetrushev, Bogdan Fetica, Mindra-Eugenia Badea, Madalina Moldovan-Lazar, Manuela Lenghel , Csaba Csutak, Andrei Roman, Sergiu Pasca, Alina-AndreeaZimta, CiprianJitaru , CiprianTomuleasa and Rares-Calin Roman.

16. [Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?](#)

Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, PatricTeodorescu, Catalin Vlad, **Sabina Iluta**, Delia Dima, Dana Tomescu, EcaterinaScarlatescu, Alina Tanase, Olafur EysteinnSigurjonsson, Anca Colita, Hermann Einsele, CiprianTomuleasa

17. [The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients](#)

Sergiu Pasca, Cristina Turcas, AncutaJurj ,Patric Teodorescu , **Sabina Iluta**, IonutHotea, Anca Bojan, Cristina Selicean , Bogdan Fetica, BobePetrushev, Vlad Moisoiu, Alina-AndreeaZimta, Valentina Sas, Catalin Constantinescu, MihneaZdrenghea, Delia Dima and CiprianTomuleasa.

18. [Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified](#)Minodora

Desmirean , DalmaDeak , Ioana Rus , Delia Dima , **Sabina Iluta** , Alexandra Preda , Tiberiu Modovan , Andrei Roman , Ciprian Tomuleasa , BobePetrushev

19. [Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease](#)

Sabina Iluta, Sergiu Pasca, Delia Dima, Gabriela Mester, Laura Urian, Anca Bojan, Mihnea Zdrenghea Adrian Trifa, Ovidiu Balacescu, Ciprian Tomuleasa

20. [The Predictive Role of Modified Early Warning Score in 174 Hematological Patients at the Point of Transfer to the Intensive Care Unit](#)Catalin Constantinescu,Sergiu Pasca,**Sabina Iluta**,Grigore Gafencu,Maria Santa,Ciprian Jitaru, Patric Teodorescu,Delia Dima,Mihnea Zdrenghea andCiprian Tomuleasa

21. [IbrutinibMonotherapy as Bridge-to-Transplant for Relapsed/RefractoryPrimaryOculo-Cerebral Lymphoma](#)DalmaDeak-Mihaly,**Sabina Iluta**, Sergiu Pasca, Ciprian Jitaru,Andrei Roman,AlexandraAndries,Monica Padurariu-Covit,BobePetrushev,Anca Vasilache, Anca Bojan,Mihnea Zdrenghea,Angela Dascalescu,Ion Antohe, Anca Colita,Andrei Colita,Delia Dima,Alina TanaseandCiprian Tomuleasa

22. [Currenttherapeuticapproaches in the management of hemophilia—a consensusviewbythe Romanian Society of Hematology](#)IonutHotea, MelenBrinza, Cristina Blag, Alina-Andreea Zimta, NoemiDirzu, Corina Burzo, Ioana Rus, Dragos Apostu, Horea Benea, Mirela Marian, Alexandru Mester, Sergiu Pasca, **Sabina Iluta**, Patric Teodorescu, Ciprian Jitaru, Mihnea Zdrenghea, Anca Bojan, Tunde Torok-Vistai, Radu Niculescu, Cristina Tarniceriu, Delia Dima, Cristina Truica, MargitSerban, Ciprian Tomuleasa, Daniel Coriu

23. [SERS-Based Evaluation of the DNA Methylation Pattern Associated With Progression in Clonal Leukemogenesis of Down Syndrome](#)Vlad Moisoiu, Valentina Sas, Andrei Stefancu, Stefania D. Iancu, AncutaJurj, Sergiu Pasca, **Sabina Iluta**, Alina-Andreea Zimta, Adrian B. Tigu, Patric Teodorescu, Cristina Turcas, Cristina Blag, Delia Dima, Gheorghe Popa, Smaranda Arghirescu, Sorin Man, Anca Colita, Nicolae Leopold and Ciprian Tomuleasa

24. [Correlation between the prevalence of T-cell lymphomas and alcohol consumption](#) Minodra Desmirean , Cedric Richlitzki , Sergiu Pasca , Patric Teodorescu , Bobe Petrushev , Sebastian Rauch , Jakob Steinheber , **Sabina Iluta** , Jiaxin Liu , Delia Dima , Ravnit Grewal , Weina Ma , Liren Qian , Ciprian Tomuleasa
25. [The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A](#) Alina-Andreea Zimta, Ionut Hotea, Melen Brinza, Cristina Blag, **Sabina Iluta**, Catalin Constantinescu, Atamyrat Bashimov, Elisabeth-Antonia Marchis-Hund, Alexandra Coudsy, Laetitia Muller-Mohnssen, Noemi Dirzu, Diana Gulei, Delia Dima, Margit Serban, Daniel Coriu and Ciprian Tomuleasa
26. [A narrative review of central nervous system involvement in acute leukemias](#) Dalma Deak I, Nicolae Gorcea-Andronic, Valentina Sas, Patric Teodorescu, Catalin Constantinescu, **Sabina Iluta**, Sergiu Pasca, Ionut Hotea, Cristina Turcas, Vlad Moisoiu, Alina-Andreea Zimta, Simona Galdean, Jakob Steinheber, Ioana Rus, Sebastian Rauch, Cedric Richlitzki, Raluca Munteanu, Ancuta Jurj, Bobe Petrushev, Cristina Selicean, Mirela Marian, Olga Soritau, Alexandra Andries, Andrei Roman, Delia Dima, Alina Tanase, Olafur Sigurjonsson, Ciprian Tomuleasa
27. [B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?](#) Minodora Desmirean, Sebastian Rauch, Ancuta Jurj, Sergiu Pasca, **Sabina Iluta**, Patric Teodorescu, Cristian Berce, Alina-Andreea Zimta, Cristina Turcas, Adrian-Bogdan Tigiu, Cristian Moldovan, Irene Paris, Jakob Steinheber, Cedric Richlitzki, Catalin Constantinescu, Olafur Eysteinn Sigurjonsson, Delia Dima, Bobe Petrushev and Ciprian Tomuleasa
28. [MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members](#) Valentina Sasa, Sergiu Pasca, Ancuta Jurj, Laura Pop, Hideki Muramatsu, Hiroko Ono, Delia Dima, Patric Teodorescu, **Sabina Iluta**, Cristina Turcas, Anca Onaciu, Raluca Munteanu, Alina-Andreea Zimta, Cristina Blag, Gheorghe Popa, Elias Daniel Alexander von Gamm, Smaranda Arghirescu, Margit Serbanh, Sorin Man, Mirela Marian, Bobe Petrushev, Cristian Berce, Anca Colita, Mihnea Zdrengea, Seiji Kojima, Diana Gulei, Yoshiyuki Takahashie, Ciprian Tomuleasa
29. ["Lazarus Response" When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy.](#) Tomai RA, **Iluta S**, Tigiu AB, Nistor M, Bancos A, Cenariu D, Jitaru C, Patcas S, Dima D, Kegyes D, Buruiana S, Zdrengea M, Tanase AD, Tomuleasa C, Micu R. *Diagnostics (Basel)*. 2024 Sep 20;14(18):2084. doi: 10.3390/diagnostics14182084. PMID: 39335764
30. [Single low-dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage.](#) Jitaru C, Peters MC, Aggarwal L, Bancos A, Tigiu AB, Cenariu D, Selicean C, Pasca S, Moisoiu V, Rotariu P, Santa M, **Iluta S**, Drula R, Kegyes D, Kurtus A, Zdrengea M, Gondek L, Tomuleasa C, Ghiur G. *J Cell Mol Med*. 2024 Oct;28(20):e18592. doi: 10.1111/jcmm.18592. PMID: 39435884

PARTICIPARI LA CONFERINTE SI CONGRESE NATIONALE SI INTERNATIONALE

2017, March 10-11, Cluj Napoca, Romania: Insights in Hematology, 2nd edition

2017, October 4-8, Sinaia, Romania: 24th National Conference of Clinical Hematology and Transfusion Medicine

2018, January 19-20, Vienna, Austria: 17th European Multiple Myeloma Academy

2018, March 9-10, Cluj-Napoca, Romania: Insights in Hematology, 3rd edition

2018, October 10-14, Sinaia, Romania: 25th National Conference of Clinical Hematology and Transfusion Medicine

2019, February 1-2, Vienna, Austria: 19th European Multiple Myeloma Academy

2019, May 9-11, Bucharest, Romania: National Congress of the Romanian Society for Bone Marrow Transplant

2019, May 13-14, Cluj-Napoca, Romania: Insights in Hematology, 4th edition

2019, June 18-22, Lugano, Switzerland: 15th International Conference on Malignant Lymphoma

2019, December 04-10, 61st ASH Annual Meeting, Florida, Orlando, USA

2020, EHA 25 virtual

2021 National Congress of the Romanian Society for Bone Marrow Transplant, November- virtual- speaker

2021 December 2021, 63rd ASH Annual Meeting, Atlanta, USA,

2022 January 27-29, 25th European Multiple Myeloma Academy, Vienna, Austria

2022, March 17-20th 2nd Translational Research E-Conference CHRONIC LYMPHOCYTIC LEUKAEMIA - Virtual

2022, March 19-23, 48th EBMT Annual Meeting – Virtual

2022, May 30-June 2th Cantera Meeting, Lecce, Italy

2022, June 8th-17th, EHA Hybrid

2022, October 19th-21, Lymphoma Working Party Educational Course-virtual- speaker

2022, November 25 - December 2nd Project AURORA mobility, Iceland, Reykjavik

2022, December 8th- 14th, ASH, New Orleans , ASH, USA

2023, March 3rd- 13th, ERASMUS, New Delhi, India

2023, June 8th- 15th, EHA, Frankfurt, Germany

2023, June 30th -July 1st, EMMA, Madrid, Spain

2023, August 30th – September 11th, ERASMUS, Beijing, China

2024, May Insights in Hematology, Cluj-Napoca, Romania

2024, May, SRTM National Conference, Cluj-Napoca, Romania

2024, May, T-Cell Project Investigator Meeting, Buenos Aires, Argentina

2024, October 04-05, ESH Multiple Myeloma, Mandelieu-La Napoule, France

2025, January 24-25, 31th European Multiple Myeloma Academy, Vienna, Austria

2025, May, Insights in Hematology, Cluj-Napoca, Romania

Data 24.07.2025

Nume si semnatura

ILUTA SABINA IOANA DOINITA